Agilon Health, Inc. (NYSE: AGL) is a Healthcare company in the Medical - Care Facilities industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
Latest market price
94.78
+0.67+0.71%
Earnings
Up 0.7% — Reported earnings — EPS beat by 73%, revenue beat by 3%.
High confidence
TA
Loading chart...
Snapshot
| Index | - | P/E | - | EPS (ttm) | -22.70 | Insider Own | - | Shs Outstand | 16.68M | Perf Week | -4.40% |
| Market Cap | 1.58B | Forward P/E | - | EPS next Y | -0.94 | Insider Trans | 0.12% | Shs Float | 11.71M | Perf Month | -11.91% |
| Enterprise Value | 1.38B | PEG | - | EPS next Q | - | Inst Own | - | Short Float | 7.34% | Perf Quarter | 251.82% |
| Income | -373.00M | P/S | 0.27 | EPS this Y | 86.60% | Inst Trans | - | Short Ratio | 2.08 | Perf Half Y | 357.87% |
| Sales | 5.82B | P/B | 8.74 | EPS next Y | 69.13% | ROA | -24.82% | Short Interest | 859.44K | Perf YTD | 450.41% |
| Book/sh | 10.85 | P/C | 6.85 | EPS next 5Y | - | ROE | -146.01% | 52W High | 133.04 -28.76% | Perf Year | 123.01% |
| Cash/sh | 13.85 | P/FCF | - | EPS past 3/5Y | - | ROIC | -158.86% | 52W Low | 7.48 1167.11% | Perf 3Y | -79.91% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | 35.44% 37.25% | Gross Margin | -2.74% | Volatility | 7.71% 8.67% | Perf 5Y | -89.74% |
| Dividend TTM | - | EV/Sales | 0.24 | EPS Y/Y TTM | -44.13% | Oper. Margin | -6.75% | ATR (14) | 9.60 | Perf 10Y | - |
| Dividend Ex-Date | Nov 16, 2011 | Quick Ratio | 1.04 | Sales Y/Y TTM | -3.99% | Profit Margin | -6.42% | RSI (14) | 41.37 | Recom | 2.80 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.04 | EPS Q/Q | - | SMA20 | -13.43% | Beta | 2.98 | Target Price | 67.00 |
| Payout | 0.00% | Debt/Eq | 0.29 | Sales Q/Q | -7.37% | SMA50 | -10.26% | Rel Volume | 1.09 | Prev Close | 94.11 |
| Employees | 856 | LT Debt/Eq | 0.14 | Earnings | Aug 05 | SMA200 | 119.56% | Avg Volume | 398.94K | Price | 94.78 |
| IPO Date | Apr 15, 2021 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 72.99% 2.94% | Net Debt/EBITDA | 0.31 | Volume | 433,424 | Change | 0.71% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Jul-23-26 | Downgrade | Citigroup | Neutral → Sell | |
| Jul-13-26 | Reiterated | Wells Fargo | Overweight | $72 → $141 |
| May-26-26 | Upgrade | Barclays | Underweight → Equal Weight | $81 |
| May-08-26 | Reiterated | Wells Fargo | Overweight | $1.50 → $72 |
| May-07-26 | Upgrade | Deutsche Bank | Hold → Buy | $33 → $49 |
| May-07-26 | Upgrade | Jefferies | Hold → Buy | $1.10 → $48 |
| May-04-26 | Downgrade | JP Morgan | Neutral → Underweight | |
| Apr-09-26 | Reiterated | Deutsche Bank | Hold | $2.00 → $33 |
| Apr-08-26 | Reiterated | Evercore ISI | In Line | $16 |
| Oct-07-25 | Reiterated | Wells Fargo | Overweight | $1.50 |
Latest News
Aug-04-26
Jul-29-26
Jul-29-2609:14AM
Jul-27-26
Jul-27-2610:00AM
Jul-23-26
07:00AM
Jul-13-26
Jul-13-2610:24AM
Jul-10-26
Jul-10-2608:30AM
Jul-07-26
Jul-07-2604:05PM
Jun-30-26
Jun-24-26
Company
Agilon Health, Inc. provides healthcare solutions specifically designed for older adults, delivered through local primary care physicians throughout the United States. As of December 31, 2021, the company served an approximate total of 238,000 senior clients. This figure included 186,300 individuals enrolled in Medicare Advantage plans and 51,700 recipients of Medicare fee-for-service benefits. The enterprise, which commenced operations in 2016, was initially incorporated as Agilon Health Topco, Inc. before rebranding to its current name, agilon health, inc., in March 2021. Its corporate headquarters are situated in Austin, Texas.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 5,819 | 5,933 | 6,061 | 4,316 | 2,388 | 1,521 | 1,218 | 794 | |
| Cost of Goods Sold Incl. D&A | 5,979 | 6,121 | 6,056 | 4,247 | 2,277 | 1,456 | 1,124 | 766 | |
| Gross Profit | -160 | -189 | 5 | 70 | 111 | 66 | 94 | 29 | |
| Selling, General and Administrative Excl. Other | 226 | 239 | 269 | 286 | 208 | 428 | 137 | 123 | |
| Research and Development | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Other Operating Expense | 8 | -7 | 28 | 16 | 9 | 10 | 14 | 12 | |
| Operating Income | -393 | -421 | -292 | -232 | -105 | -372 | -57 | -107 | |
| Interest Expense | 4 | 7 | 6 | 7 | 4 | 6 | 8 | 9 | |
| Unusual Expense | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 24 | 24 | 49 | 44 | 19 | -5 | 2 | 1 | |
| Net Income Before Taxes | -373 | -404 | -249 | -194 | -91 | -383 | -62 | -115 | |
| Income Taxes | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 0 | |
| Consolidated Net Income | -373 | -405 | -260 | -263 | -107 | -406 | -60 | -283 | |
| Net Income From Continuing Operations | -373 | -405 | -250 | -195 | -92 | -384 | -63 | -114 | |
| Net Income | -373 | -405 | -260 | -263 | -107 | -406 | -60 | -283 | |
| EPS (Recurring) | -22.70 | -24.50 | -15.75 | -16.00 | -6.50 | -27.25 | -4.00 | -18.50 | |
| EPS (Basic, Before Extraordinaries) | -22.70 | -24.50 | -15.75 | -16.00 | -6.50 | -27.25 | -4.00 | -18.50 | |
| EPS (Diluted) | -22.70 | -24.50 | -15.75 | -16.00 | -6.50 | -27.25 | -4.00 | -18.50 | |
| EBITDA | -340 | -369 | -218 | -168 | -72 | -362 | -40 | -64 | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 0.28 | 0.05 | 0.13 | 1.16 | 2.70 | 6.66 | — | — | |
| Gross Margin | -2.75 | -3.19 | 0.08 | 1.62 | 4.65 | 4.34 | 7.72 | 3.65 | |
| Operating Margin | -6.75 | -7.10 | -4.82 | -5.38 | -4.40 | -24.46 | -4.68 | -13.48 | |
| Net Margin | -6.41 | -6.83 | -4.29 | -6.09 | -4.48 | -26.69 | -4.93 | -35.64 | |
| Shares Outstanding | 17 | 17 | 16 | 16 | 16 | 15 | 15 | 15 | |
| Market Capitalization | 1,611 | 293 | 760 | 5,020 | 6,456 | 10,125 | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Shaker Benjamin | Chief Markets Officer | Mar 02 '26 | Buy | 0.60 | 500,000 | 301,050 | 1,367,674 | Mar 03 |
| Wulf John William | Director | Nov 12 '25 | Buy | 0.63 | 81,000 | 50,941 | 365,857 | Jan 30 |
| Schwaneke Jeffrey A. | Chief Financial Officer | Nov 29 '23 | Buy | 11.22 | 44,600 | 500,412 | 31,931 | Apr 03 |
| Shaker Benjamin | Chief Markets Officer | Mar 14 '25 | Buy | 0.00 | 11,786 | 0 | 461,201 | Mar 18 |
| Venkatachaliah Girish | Chief Technology Officer | Mar 14 '25 | Buy | 0.00 | 9,429 | 0 | 158,431 | Mar 18 |
| Sell Steven | CEO & President | Mar 14 '25 | Buy | 0.00 | 42,426 | 0 | 370,873 | Mar 18 |
| McLoughlin Karen | Director | Dec 13 '24 | Buy | 2.20 | 25,000 | 55,085 | 73,166 | Dec 13 |
| Battaglia Silvana | Director | Dec 11 '24 | Buy | 2.01 | 25,062 | 50,269 | 66,144 | Dec 13 |
| MCKENZIE DIANA | Director | Dec 09 '24 | Buy | 2.20 | 7,500 | 16,489 | 58,819 | Dec 11 |
| Wulf John William | Director | Dec 05 '24 | Buy | 2.18 | 45,000 | 98,145 | 206,133 | Dec 11 |
| MCKENZIE DIANA | Director | Nov 25 '24 | Buy | 2.28 | 12,500 | 28,474 | 51,319 | Dec 11 |
| Sell Steven | CEO & President | Sep 12 '24 | Buy | 3.36 | 20,000 | 67,188 | 67,590 | Sep 16 |
| Desai Veeral | Chief Strategy & Dev. Officer | Mar 14 '24 | Buy | 0.00 | 11,956 | 0 | 311,541 | Mar 18 |
| Bensley Timothy | Chief Financial Officer | Mar 14 '24 | Buy | 0.00 | 14,945 | 0 | 50,116 | Mar 18 |
| Kornitzer Benjamin | Chief Med. & Quality Officer | Mar 14 '24 | Buy | 0.00 | 5,434 | 0 | 63,941 | Mar 18 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.